Tags

Type your tag names separated by a space and hit enter

Height, sitting height, and leg length in relation with breast cancer risk in the E3N cohort.
Cancer Epidemiol Biomarkers Prev. 2012 Jul; 21(7):1171-5.CE

Abstract

BACKGROUND

If height is a well-established risk factor for breast cancer, leg length and sitting height are usually considered as better candidate biomarkers of growth hormone exposure than height, respectively, in pre- and postpuberty.

METHODS

Risk of breast cancer associated with quartiles of height, sitting height, and leg length were estimated in the French E3N cohort (N = 50,704, including 2,065 breast cancer cases), stratified on both menopausal and hormone receptor statuses.

RESULTS

Height was associated with an increased postmenopausal breast cancer risk [HR = 1.22 (1.06-1.41) when comparing extreme categories, P(trend) = 0.002], which was exclusively driven by the association with leg length [HR = 1.21 (1.05-1.39), P(trend) = 0.013] and not sitting height [HR = 1.03 (0.89-1.18), P(trend) = 0.379]. Leg length was associated with an increased ER(+) breast cancer risk in postmenopausal [HR = 1.24 (1.06-1.46), P(trend) = 0.004], whereas sitting height was associated with a borderline decreased ER(-) premenopausal breast cancer risk [HR = 0.45 (0.20-1.01), P(trend) = 0.011]. The positive associations observed in the overall population between leg length and breast cancer risk were actually restricted to women who had a short birth length [HR = 1.82 (1.22-2.72), P(trend) = 0.022] and those with a low birth weight [HR = 1.43 (1.00-2.04), P(trend) = 0.054].

CONCLUSION

The two components of height risk are differentially associated with breast cancer risk: leg length with an increased risk of postmenopausal ER(+) tumors and sitting height with a decreased risk of premenopausal ER(-) tumors.

IMPACT

Future prospective studies should no longer consider height a single risk factor for breast cancer risk.

Authors+Show Affiliations

INSERM (Institut National de la Santé et de la Recherche Médicale) U1018, Center for Research in Epidemiology and Population Health (CESP), 94805 Villejuif Cedex, France.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22623708

Citation

Fagherazzi, Guy, et al. "Height, Sitting Height, and Leg Length in Relation With Breast Cancer Risk in the E3N Cohort." Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology, vol. 21, no. 7, 2012, pp. 1171-5.
Fagherazzi G, Vilier A, Boutron-Ruault MC, et al. Height, sitting height, and leg length in relation with breast cancer risk in the E3N cohort. Cancer Epidemiol Biomarkers Prev. 2012;21(7):1171-5.
Fagherazzi, G., Vilier, A., Boutron-Ruault, M. C., Clavel-Chapelon, F., & Mesrine, S. (2012). Height, sitting height, and leg length in relation with breast cancer risk in the E3N cohort. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology, 21(7), 1171-5. https://doi.org/10.1158/1055-9965.EPI-12-0130
Fagherazzi G, et al. Height, Sitting Height, and Leg Length in Relation With Breast Cancer Risk in the E3N Cohort. Cancer Epidemiol Biomarkers Prev. 2012;21(7):1171-5. PubMed PMID: 22623708.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Height, sitting height, and leg length in relation with breast cancer risk in the E3N cohort. AU - Fagherazzi,Guy, AU - Vilier,Alice, AU - Boutron-Ruault,Marie-Christine, AU - Clavel-Chapelon,Françoise, AU - Mesrine,Sylvie, Y1 - 2012/05/23/ PY - 2012/5/25/entrez PY - 2012/5/25/pubmed PY - 2012/12/12/medline SP - 1171 EP - 5 JF - Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology JO - Cancer Epidemiol. Biomarkers Prev. VL - 21 IS - 7 N2 - BACKGROUND: If height is a well-established risk factor for breast cancer, leg length and sitting height are usually considered as better candidate biomarkers of growth hormone exposure than height, respectively, in pre- and postpuberty. METHODS: Risk of breast cancer associated with quartiles of height, sitting height, and leg length were estimated in the French E3N cohort (N = 50,704, including 2,065 breast cancer cases), stratified on both menopausal and hormone receptor statuses. RESULTS: Height was associated with an increased postmenopausal breast cancer risk [HR = 1.22 (1.06-1.41) when comparing extreme categories, P(trend) = 0.002], which was exclusively driven by the association with leg length [HR = 1.21 (1.05-1.39), P(trend) = 0.013] and not sitting height [HR = 1.03 (0.89-1.18), P(trend) = 0.379]. Leg length was associated with an increased ER(+) breast cancer risk in postmenopausal [HR = 1.24 (1.06-1.46), P(trend) = 0.004], whereas sitting height was associated with a borderline decreased ER(-) premenopausal breast cancer risk [HR = 0.45 (0.20-1.01), P(trend) = 0.011]. The positive associations observed in the overall population between leg length and breast cancer risk were actually restricted to women who had a short birth length [HR = 1.82 (1.22-2.72), P(trend) = 0.022] and those with a low birth weight [HR = 1.43 (1.00-2.04), P(trend) = 0.054]. CONCLUSION: The two components of height risk are differentially associated with breast cancer risk: leg length with an increased risk of postmenopausal ER(+) tumors and sitting height with a decreased risk of premenopausal ER(-) tumors. IMPACT: Future prospective studies should no longer consider height a single risk factor for breast cancer risk. SN - 1538-7755 UR - https://www.unboundmedicine.com/medline/citation/22623708/Height_sitting_height_and_leg_length_in_relation_with_breast_cancer_risk_in_the_E3N_cohort_ L2 - http://cebp.aacrjournals.org/cgi/pmidlookup?view=long&pmid=22623708 DB - PRIME DP - Unbound Medicine ER -